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Abstract
The cis-acting signals found at the 3 ends of the genomic and antigenomic RNAs are a major factor determining the level of
paramyxovirus RNA replication from each promoter. Using a minigenome system that reconstitutes SV5 RNA synthesis from cDNA-
derived components, we show here that the genomic promoter (GP) for the paramyxovirus SV5 directs RNA replication 14-fold lower
than that seen from the antigenomic promoter (AGP). The goal of this study was to identify cis-acting signals responsible for differential
levels of RNA replication from the SV5 GP and AGP. We have previously shown that the SV5 AGP contains three sequence-dependent
elements (CRI, CRII, and Region III) that are separated by sequence-independent spacer regions. Minigenomes containing chimeric
promoters were constructed to test the hypothesis that transfer of discrete cis-acting AGP elements to the GP could confer higher replication
properties to the GP. Minigenomes containing a substitution of the AGP CRI, CRII, or Region III elements alone in place of the
corresponding GP sequences did not show enhanced levels of RNA replication. However, transfer of both the AGP 3 terminal CRI and
Region III elements into the corresponding sites of the GP led to a minigenome which replicated to 40% of the levels seen with the AGP.
This enhanced RNA replication from the GP was further increased up to AGP levels by also including the intervening AGP segment (bases
20–50) located between CRI and Region III. Importantly, transfer of nonviral sequences in place of GP bases 20–50 also increased RNA
replication to levels approaching that of the AGP, but only in the context of the AGP CRI and Region III substitutions. These data indicate
that differential levels of RNA replication from the SV5 GP and AGP are due to a combination of positive-acting signals in the AGP (CRI
and Region III) and a negative-acting signal in the GP (bases 20–50). Possible functions for the SV5 promoter elements in determining RNA
replication levels are proposed.
© 2003 Elsevier Science (USA). All rights reserved.
Introduction
The paramyxovirus genomic and antigenomic RNAs
contain 3 end cis-acting signals that are a major factor
controlling viral RNA replication (Calain and Roux, 1993;
Fearns et al., 2002; Hoffman and Banerjee, 2000b; Keller et
al., 2001; Taparrel and Roux, 1996). Typically, viral ge-
nomes are found at high levels compared to antigenomic
RNA (Kolakofsky and Bruschi, 1975; Le Mercier et al.,
2002; Mottet and Roux, 1989). These genomic RNAs serve
at least three functions in the growth cycle: incorporation
into progeny virions, acting as a template for producing
mRNAs, and acting as a template for antigenome synthesis
(Lamb and Kolakofsky, 2001). By contrast, antigenomic
RNA is typically found in lower amounts and apparently
functions only as a template to amplify genomic RNA.
Thus, paramyxovirus RNA replication directed by the
genomic promoter (GP) to produce antigenomes is typically
much lower than that from the antigenomic (AGP) which
produces genomes. In this report, we have identified cis-
acting signals in the GP and AGP that are responsible for
differential RNA replication for the prototypic paramyxo-
virus simian virus 5 (SV5).
Paramyxoviruses are a diverse family of enveloped vi-
ruses whose genome is composed of a single strand of
* Corresponding author. Fax: 1-336-716-9928.
E-mail address: gparks@wfubmc.edu (G.D. Parks).
R
Available online at www.sciencedirect.com
Virology 306 (2003) 347–358 www.elsevier.com/locate/yviro
0042-6822/03/$ – see front matter © 2003 Elsevier Science (USA). All rights reserved.
doi:10.1016/S0042-6822(02)00071-5
negative-sense RNA (Lamb and Kolokofsky, 2001). Proto-
typic paramyxoviruses that have been extensively studied
include Sendai virus (SeV), measles virus, and respiratory
syncytial virus (RSV). These viruses are members of the
respiro-, morbilli-, and pneumoviruses, respectively. SV5 is
the prototype of the rubulaviruses, which also includes
mumps virus, SV41, and human parainfluenza virus type 2
(HPIV2).
While paramyxoviruses share many general features of
viral RNA replication, reverse genetics systems (reviewed
in Conzelmann, 1996; Nagai, 1999; Palese et al., 1996) have
uncovered significant differences in requirements for cis-
acting sequences in the genomic and antigenomic RNAs
(Durbin et al., 1997; Fearns et al., 2002; Hoffman and
Banerjee, 2000a; Keller et al., 2001; Murphy et al., 1998;
Taparrel and Roux, 1996). For example, the overall length
of a paramyxovirus RNA template can be a major factor
determining the level of RNA replication, with genome
replication being most efficient when the total number of
nucleotides is an even multiple of six (Calain and Roux,
1993; Kolakofsky et al., 1998). Recent results from the
analysis of SeV minigenomes supports a model for the
“rule-of-six” constraint in which the viral promoter se-
quences must be recognized in the context of NP monomers,
each of which binds six nucleotides (Egelman et al., 1989).
The degree to which replication of a particular paramyxo-
virus genome adheres to the rule-of-six requirement differs
among viruses. For SeV, the rule of six is an apparent strict
requirement for RNA replication (Calain and Roux, 1993),
although expression of the SeV C protein can have a pro-
found effect on the stringency for 6N length genomes (Tap-
parel et al., 1997). By contrast, there is no replicative ad-
vantage to RSV genome analogs having 6 N-length
genomes (Samal and Collins, 1996). For SV5 and HPIV3,
the rule-of-six requirement is intermediate between the
stringencies found previously for SeV and RSV (Murphy
and Parks, 1997; Durbin et al., 1997).
The promoters for paramyxovirus RNA replication are
major determinants of the level of RNA replication and are
located at the 3 ends of the genomic and antigenomic
RNAs (reviewed in Lamb and Kolakofsky, 2001). For SV5,
previous mutational analyses have identified three discon-
tinuous sequence-dependent elements required for optimal
RNA replication from the AGP (Keller et al., 2001; Murphy
et al., 1998; Murphy and Parks, 1999). Conserved Region I
(CRI) is composed of the 3 terminal 19 nucleotides and
was identified through a sequence alignment as a region that
is highly conserved between rubulavirus antigenomes
(Fig. 1). Conserved Region II (CRII) was identified by
mutational analysis as an internal promoter element within
the coding region of the L protein gene located 73 to 90
from the 3 end of the antigenomic RNA (Fig. 1; Murphy
and Parks, 1998). Extensive mutagenesis (Murphy and
Parks, 1999) has defined an important motif in the SV5
AGP CRII as a 3-GC-5 dinucleotide pair located in the
first two positions of three sequential hexamers of nucleo-
tides (template strand, 3-AGGAGCGGUAGCUAGGGC-
5; Fig. 1). SeV genomic and antigenomic RNAs also con-
tain an internal promoter element corresponding to the SV5
CRII (Taparrel and Roux, 1998). Remarkably, the SeV
internal element differs from SV5 in both location (bases
79–96) as well as sequence composition (template strand,
3-CNNNNN-5). For the SV5 AGP, a third promoter ele-
ment (bases 51–66; boxed Region III; Fig. 1) has been
identified that is not essential for RNA replication, but
appears to act as an enhancer.
The goal of the experiments described here was to define
the cis-acting elements responsible for differential levels of
RNA replication directed by the SV5 GP and AGP. A
sequence alignment of the 90 bases at the 3 end of the
genomic and antigenomic RNA shows that while the GP
contains CRI and CRII elements, the equivalent of the AGP
Region III is occupied in the GP by a segment encoding the
NP transcriptional start site (Fig. 1). We have tested the
hypothesis that the SV5 GP lacks positive-acting signals for
high levels of RNA replication and that transfer of discrete
elements (i.e., CRI, CRII, or Region III) from the AGP to
the GP could confer higher RNA replication properties to
the GP. Our results indicate that differential RNA replica-
tion from the SV5 GP and AGP is due to a combination of
positive-acting sequences in the AGP and also a negative-
acting segment in the GP. Possible functions for the SV5
promoter elements in determining RNA replication levels
are discussed.
Results
The genomic 3 terminal 90 bases direct optimal RNA
transcription and replication
Previous work has shown that the 3 terminal 90 bases of
the SV5 AGP are the minimal sequence that can direct
efficient RNA replication (Murphy and Parks, 1997), and
this has been confirmed through mutational analyses (Mur-
phy et al., 1998). However, the minimal sequences required
for the SV5 GP to direct optimal RNA synthesis had not
been determined.
A minigenome (90GP-GL) was constructed that con-
tained a reporter gene GL flanked on the 3 end by the
terminal 90 bases of genomic RNA and on the 5 end by 113
bases of 5 L-trailer sequences (Fig. 2A). RNA synthesis
from the 90GP-GL minigenome was compared to a previ-
ously described minigenome AGP-GL (Murphy et al.,
1998), which differs only by having 90 bases of antigeno-
mic RNA, instead of genomic RNA, at the 3 end. RNA
synthesis directed by these two minigenomes was assayed
using a previously described transfection system that recon-
stitutes RNA synthesis from cDNA-derived components
(Murphy et al., 1998; Rassa and Parks, 1999). Briefly, A549
cells were infected with a recombinant vaccinia virus ex-
pressing T7 RNA polymerase (vacT7; Fuerst et al., 1986)
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and then transfected with plasmids expressing the SV5 NP,
P, and L proteins. The transfection mix also included a
plasmid expressing a negative-sense RNA corresponding to
the minigenome 90GP-GL or AGP-GL. To detect products
of SV5 RNA replication, cell lysates were treated with
micrococcal nuclease to digest RNAs not encapsidated by
NP (Peeples and Collins, 2000), and RNA was extracted.
RNA transcription products were isolated from parallel
samples using oligo(dT) cellulose (Rassa and Parks, 1999).
To detect RNAs synthesized by the L polymerase, rather
than the T7 polymerase, RNA samples were analyzed by
Northern blotting with a GL-specific riboprobe that was the
same polarity as the cDNA-derived T7 transcript. As shown
in Fig. 2B, the 90-base GP directed RNA replication to
7% that of the WT AGP (compare lanes 1 and 3). As
expected, the GP directed the synthesis of a polyadenylated
transcription product, while the AGP could not direct tran-
scription (Fig. 2B, lanes 1 and 3, transcription panel). These
data indicate that the GP is much weaker than the AGP in its
ability to direct RNA replication and that the GP directs
predominantly mRNA transcription rather than replication
products.
The alignment in Fig. 1 also shows a region located 5 to
CRII that has a relatively high degree of sequence identity,
with bases 97–109 being identical in 9 of 13 bases. While
previous results have shown this region is not required for
optimal replication from the SV5 AGP (Murphy et al.,
1998), the role of this conserved region in RNA synthesis
from the SV5 GP has not been determined. This raises the
possibility that additional sequences are required.
To determine if additional sequences past base 90 con-
tributed to differences in RNA synthesis from the GP and
AGP, a minigenome (180GP-GL, Fig. 2B) was constructed
to contain additional 3 end sequences that extended up to
the NP translational start codon at base 180 (Parks et al.,
1992). When analyzed in the vacT7 transfection assay,
levels of RNA replication as well as transcription from the
180GP minigenome closely matched that seen with the
minigenome containing the 90-base GP (Fig. 2B, compare
lanes 3 and 5). Thus, the sequences necessary for optimal
RNA replication and transcription are contained within the
3 terminal 90 bases of genomic RNA. To determine if
decreasing the size of the GP altered RNA synthesis, the
minigenome 60GP-GL was constructed to contained only
the first 60 bases of 3 genomic RNA, but not CRII found
from bases 73–90 (Fig. 2B). As shown in Fig. 2B, the
Fig. 1. Sequence comparison of the SV5 GP and AGP. The 3-terminal 113 bases from the genomic and antigenomic RNA of SV5 are listed. Ninety bases
of 3 genomic RNA are designated as SV5 GP (GP) and the 90 bases of 3 antigenomic RNA are designated as SV5 AGP (AGP). The arrow at base 56 of
the GP denotes the transcriptional start site of the NP gene. Amino acids that are encoded in the 3 end of the SV5 L gene are designated by one-letter
abbreviations above the AGP sequence. The site for the poly(A) addition to the L mRNA is underlined. Conserved Region I (CRI; 3 terminal), conserved
Region II (CRII; within the NP or L gene, for the genomic or AGP, respectively), Region III are indicated by boxes. Filled circles denote positions of sequence
identity.
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signals surrounding the NP transcriptional start site in the
truncated minigenome differ by 3 bases from the WT start
site because of the linkage with the GL segment, but still
closely resemble the consensus site previously published
(Rassa and Parks, 1999). When assayed in the vacT7 sys-
tem, no viral RNA transcription or replication products
from the 113-GL-60GP minigenome were detected (Fig. 2B
lane 4). Although these data indicate that CRII is required
for both RNA replication and RNA transcription from the
GP, the minimum sequences between bases 60 and 90 that
are needed for a functional GP have not been further de-
fined.
The above results support the proposal that the SV5 GP
is inherently a weaker promoter for RNA replication than
the AGP, since the GP directs 14-fold lower RNA repli-
cation. Titration experiments were carried out to determine
if RNA replication from the GP could approach or exceed
that seen from the AGP by increasing the levels of NP. Cells
were transfected with a constant amount of plasmids ex-
pressing L, P, and a minigenome containing either the
wild-type (WT) GP or the WT AGP, along with increasing
amounts of the plasmid expressing NP. RNA replication
products were isolated and analyzed by Northern blotting.
As shown in Fig. 2C, RNA replication from the AGP
showed a broad titration with an optimal level seen using 3
g of transfected NP plasmid. RNA replication from the GP
Fig. 2. The 3 terminal 90 bases of SV5 genomic RNA directs optimal levels of RNA synthesis. (A) Schematic of the minigenomes used in the in vivo
replication/transcription assay. The Green Lantern gene (GL) is flanked on the 3 end by the 90-base GP or AGP with CRI and CRII designated by I and
II and on the 5 end by 113 bases of the L/trailer sequence (striped box). The sequences between CRI and CRII are shown for the copyback (113-GL-AGP)
or internal deletion (113-GL-90GP) minigenomes and for minigenomes containing deletions or extensions of the GP (113-GL-60GP or 113-GL-180GP,
respectively). CRI and CRII are shown as boxes, but have different sequences (see Fig. 1). Region III found from bases 51–66 of the AGP is boxed. The
NP transcription start site (arrow at base 56) is only found in the GP. 113-GL-60GP and 113-GL-180GP have a GP containing the first 60 bases of 3 genomic
RNA or the 90-base GP along with 90 bases extending to the translational start site of NP, respectively. Underlined sequence for 113-GL-60GP denotes the
StuI restriction site linking the truncated promoter to GL. Relative replication and transcription for each template are expressed as a percentage of the level
determined for the WT template analyzed in parallel (average  SD). (B) A representative Northern blot for levels of replication and transcription from
minigenomes containing WT and mutant GP. Lane -L, transfected cells in which the L plasmid was omitted. (C) Effect of amount of transfected NP plasmid
on RNA replication from 113-GL-AGP or 113-GL-90GP.
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was also optimal using 3 g transfected NP plasmid, but
maximal replication levels were always much lower than
those seen with the AGP. The ratio of RNA replication to
transcription from the GP was not significantly altered by
transfecting increased levels of NP plasmid (not shown).
Taken together, these results indicate that the SV5 GP is
inherently weaker than the AGP in its ability to direct RNA
replication.
High-level RNA replication can be altered by exchanges
of AGP and GP CRI, but not CRII, sequences
As shown in Fig. 1, the SV5 GP has sequences corre-
sponding to the AGP CRI and CRII. Based on this high
sequence identity, we hypothesized that CRI and CRII ele-
ments within the AGP and GP could be interchanged with-
out affecting RNA replication. To test this hypothesis, mini-
genome Mutants 1–3 were constructed such that the 3 GP
(Fig. 3A, gray boxes) contained an exchange of the AGP
CRI alone, CRII alone, or CRI  CRII (black boxes). For
example, Mutant 1 contains the AGP CRI sequences (black
box) substituted in place of the corresponding 3 end seg-
ment in the GP to give the AGP-I/GP chimera (AGP CRI
transferred into the 3 end GP). RNA replication levels from
Mutants 1–3 were analyzed by Northern blotting and ex-
pressed as a percentage of the WT GP as well as WT AGP
(Fig. 3A and C). When the AGP CRI (Mutant 1) or CRI 
CRII (Mutant 3) was substituted into the GP, RNA replica-
Fig. 3. RNA replication is altered in minigenomes containing exchanges of the GP and AGP CRI and CRII sequences. (A) Substitutions into the SV5 GP.
The sequence of the intervening region between the GP CRI and CRII is shown with the NP transcription start site at base 56. 113-GL-90GP is the wild-type
genomic promoter. Mutants 1–3 contain substitutions of CRI, CRII, or CRICRII from the AGP, represented as black boxes, in place of the corresponding
elements in the GP, represented as stippled boxes. The replication levels of Mutants 1–3 are expressed as percentages of the levels determined for the WT
GP and AGP minigenomes analyzed in parallel (average  SD). (B) Substitution into the SV5 AGP. The sequence of the intervening region between the
AGP CRI and CRII is shown with Region III found from bases 51–66 boxed. 113-GL-AGP is the wild-type antigenomic promoter. Mutants 4–6 contain
exchanges of CRI, CRII, or CRICRII from the GP, represented as stippled boxes, in place of the corresponding elements in the AGP, represented as black
boxes. The replication levels of Mutants 4–6 are expressed as percentages of the level determined for the WT GP minigenome (average  SD).
Representative Northern blots of replication products from Mutants 1–3 (C) or 4–6 (D) are shown. Lane -L, transfected cells in which the L plasmid was
omitted.
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tion was slightly decreased to 37 and 34% of WT GP
levels, respectively (Fig. 3A and C). Based on variability in
our minigenome assay, we have defined significant changes
in RNA synthesis as being increased fourfold or decreased
to 25% of WT levels (Rassa and Parks, 1998). Substituting
the AGP CRII into the GP did not significantly alter GP
activity, and replication was 98% that of the WT GP (Fig.
3C, Mutant 2; quantitated in Fig. 3A). Very similar results
were seen with transcription products from the mutant pro-
moters (data not shown). These data indicate that the CRII
element from the AGP can replace the CRII element in the
GP without significantly altering RNA replication. Surpris-
ingly, replacing the GP CRI with the AGP CRI resulted in
a decrease in RNA replication when exchanged individually
or with the AGP CRII (Fig. 3A and C). However, when
RNA replication is expressed as a percentage of WT AGP,
the differences in low-level replication seen between Mu-
tant 1 and Mutant 3 and WT GP are not as evident.
In the converse experiment to that in Fig. 3A, a second
set of minigenomes was constructed such that the 3 AGP
contained an exchange with the GP CRI alone, CRII alone,
or CRI  CRII (Fig. 3B, Mutants 4–6). Analysis of RNA
replication levels from these mutants showed that when the
GP CRI was transferred alone (Mutant 4) or with CRII
(Mutant 6) RNA replication levels were significantly re-
duced to 14 and 6% of WT AGP levels, respectively
(Fig. 3D; quantitated in Fig. 3B). By contrast, transferring
CRII from the GP to the AGP had little effect on RNA
replication (Fig. 3D, Mutant 5; quantitated in Fig. 3B). Two
important conclusions can be drawn from these chimeric
minigenomes. First, CRII can be exchanged between pro-
moters without significantly affecting RNA replication.
Second, CRI exchanges, alone or in combination with CRII,
decreased RNA replication from the chimeric promoters
(Fig. 3). These data indicate that CRI is not interchangeable
between the two promoters and is a negative-acting signal
for RNA replication when it is not in the proper context of
each promoter (i.e., AGP CRI with AGP; GP CRI with GP).
Identification of RNA elements from the SV5 AGP that
can confer higher RNA replication to the GP
The sequence alignment of the SV5 promoters (Fig. 1)
indicates that the GP does not contain the Region III en-
hancer found from bases 51–66 of the AGP. To determine
whether transferring only AGP Region III to the GP could
confer higher RNA replication to the GP, a minigenome
(113-GL-AGP-III/GP; Fig. 4A) was constructed such that
bases 51–66 of the GP were replaced with Region III from
the AGP. When analyzed in the vacT7 system, the Mutant
7 113-GL-AGP-III/GP minigenome did not direct the syn-
thesis of poly(A) transcription products (Fig. 4B, compare
lanes 3 and 4, transcription panel), a result that is consistent
with the removal of the NP transcriptional start site due to
replacing bases 51–66 of the GP with Region III. More
importantly, the addition of Region III to the GP did not
result in a minigenome with increased RNA replication
above levels seen with the WT GP (Fig. 4B, compare lanes
3 and 4, replication panel). Thus, while Region III acts to
promote RNA replication from the AGP (Keller et al.,
2001), it cannot by itself confer enhanced RNA replication
to the GP.
To determine which AGP elements confer increased
RNA replication to a GP, the AGP-III/GP minigenome,
which does not direct transcription but directs RNA repli-
cation to WT GP levels, was used as a backbone to make
exchanges with additional regions from the AGP. A series
of chimeric minigenomes containing Region III were con-
structed such that the GP CRI, CRII, or CRI  CRII was
replaced by the corresponding RNA elements from the AGP
(Fig. 4A, Mutants 8–10). For example, Mutant 8 contains
the AGP CRI (black box) and Region III (boxed sequences)
substituted into the GP to create the AGP-IIII/GP chi-
mera. Minigenome templates were analyzed for levels of
RNA replication using the vacT7 assay and are expressed as
a percentage of the replication levels from the WT AGP
(Fig. 4A, Mutants 8–10). Transfer of the AGP CRI and
Region III (Mutant 8) gave a reproducible increase in the
level of RNA replication to 40% of the AGP control (Fig.
4B, compare Mutant 8 and AGP lanes). By contrast, transfer
of the AGP CRII plus Region III (Mutant 9) did not signif-
icantly increase promoter activity, and the 7% levels of
RNA replication were similar to a GP containing Region III
alone (Mutant 7). Together with the results in Fig. 3 above
showing that transfer of the AGP CRI alone did not confer
higher replication to the GP, these data indicate that CRI
and Region III can promote RNA replication from the GP,
but only when present together. Unexpectedly, transfer of
all three AGP elements to the GP resulted in a minigenome
(Fig. 4C, Mutant 10) that directed RNA replication to levels
that were not above that seen with the WT GP.
Bases 1–66 of the SV5 GP contain a negative-acting
sequence that inhibits RNA replication
The above results indicated that the transfer of the AGP
CRI and Region III together in place of the corresponding
GP sequences increased RNA replication above that seen
with the WT GP (Mutant 8), but the levels were only40%
of WT AGP levels. Based on this result, we hypothesized
that the region between CRI and Region III of the AGP
might contain additional sequences that could further pro-
mote RNA replication, perhaps linking signals in CRI and
Region III. To test this, a minigenome was constructed such
that the 3 end promoter was composed of the first 66 bases
of the AGP, and the remaining bases from 67–90 were from
the GP (Fig. 5, Mutant 11). When analyzed in the vacT7
system, Mutant 11 was able to replicate to levels that were
86% that of the WT AGP (Fig. 5B). Thus, transfer of the
AGP CRI and Region III in place of the corresponding
sequences in the GP leads to an increase in RNA replication
to 40% of the AGP control, but this can be further in-
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creased to levels approaching that of the AGP when the
promoter also contains the RNA segment between the AGP
CRI and Region III.
One hypothesis to explain the enhanced replication of
Mutant 8 is that substituting the AGP region between CRI
and Region III added a positive-acting signal for replication
to the GP. Alternatively, the WT GP could have a negative-
acting signal that was removed by substituting with AGP
bases 20–50. To distinguish between these possibilities, a
minigenome was constructed such that CRI and Region III
were derived from the AGP, but bases 20–50 between CRI
and Region III were replaced with nonviral sequences (Fig.
5A, Mutant 12). Mutant 12 was found to direct RNA rep-
lication to 81% that of the WT AGP minigenome (Fig.
5B). This result indicates that enhanced replication of chi-
meric minigenome 11 is due to removal of a negative-acting
signal between bases 20 and 50 of the GP rather than
addition of a positive-acting signal from the AGP. The
effect of nonviral sequences on GP replication was only
seen in combination with the AGP CRI and Region III, as
evidenced by the finding that no increase in GP RNA
replication was observed when bases 20–50 were replaced
with nonviral sequences in the context of an otherwise WT
GP (data not shown).
To determine if the negative-acting signal between bases
20 and 50 is an extension of the CRI element or of Region
III, two additional minigenomes were constructed (Fig. 5,
Mutants 13 and 14). Both minigenomes contain the AGP
CRI and Region III and bases 67–90 of the GP. Mutants 13
and 14 differ by having bases 20–35 or 36–50 replaced with
nonviral sequences, respectively (Fig. 5A). When assayed
in the vacT7 system, Mutants 13 and 14 showed no signif-
icant increase in RNA replication over that of the GP (Fig.
5A and B). These data indicate that bases 20–50 must be
substituted to increase RNA replication to AGP levels.
Taken together, the results in Figs. 4 and 5 show that the
AGP CRI and Region III function as positive-acting signals
for RNA replication, since when transferred together they
can confer a partial increase in replication activity to the GP
(e.g., Mutant 8). In addition, bases 20–50 of the GP contain
a negative-acting signal, since replacement of this segment
with nonviral sequences increased RNA replication (e.g.,
Mutant 11), but only in the context of the AGP CRI and
Region III. However, data presented here (Figs. 3 and 5;
Fig. 4. Addition of AGP Region III and CRI to the GP results in a loss in transcription, and an increase in RNA replication. (A) Structures of WT and chimeric
minigenomes. The sequence for the intervening region is shown for each minigenome with CRI and CRII represented as a black box for the AGP and a
stippled box for GP. Region III is boxed in the AGP and the transcription start site is represented by an arrow in the GP. Mutant 7 contains Region III of
the AGP replacing bases 51–66 of the GP. Mutants 8–10 contain Region III, along with CRI, CRII, or CRIII sequences derived from the AGP, respectively.
Replication levels are expressed as percentages of the levels determined for the WT AGP minigenome (average  SD). The transcription level of Mutant
7 is expressed as a percentage of the level determined for the WT GP minigenome (90GP). ND, none detected. Representative Northern blots are shown in
B and C.
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Mutants 4, 7, and 11) indicate that the negative-acting
sequence begins in CRI of the GP and extends to base 50.
Thus, bases 1–66 of the AGP can confer higher replication
to the GP by providing positive-acting signals (CRI and
Region III) and removing a negative-acting signal.
Discussion
Current models suggest data that the relative strength of
the GP and AGP is the major factor in determining differ-
ential levels of genomic and antigenomic RNA (reviewed in
Lamb and Kolakofsky, 2001). Previous work with SeV and
HPIV3 minigenomes has shown that the AGP directs higher
levels of RNA replication than the GP and that mRNA
transcription is the major synthetic event from the GP
(Calain and Roux, 1993; Hoffman and Banerjee, 2000a;
Taparrel and Roux, 1996). Our results indicate that the SV5
GP is also a weaker promoter for RNA replication, since the
GP directs the synthesis of only 7% of the level of RNA
replication products seen with the AGP. The data presented
here suggest that the low levels of RNA replication from the
SV5 GP are due to lack of positive-acting signals present in
the AGP and the presence of a negative-acting signal in the
GP.
We have tested the hypothesis that substituting discrete
promoter elements that are important for high-level RNA
replication from the SV5 AGP alone or in combination in
place of the corresponding GP regions would confer higher
replication properties to the GP. Because the SV5 GP con-
tains CRI and CRII elements but lacks Region III (Keller et
al., 2001), an attractive possibility was that Region III alone
could confer higher replication properties to the GP. While
a GP-containing Region III substituted for bases 51–66 was
not competent for transcription, the levels of RNA replica-
tion from the chimeric promoter were not increased above
Fig. 5. Substitutions in the first 66 bases of the GP can lead to enhanced levels of RNA replication. (A) Structures of WT and chimeric minigenomes. The
sequence for the intervening region between CRI and CRII is shown for each minigenome with the AGP and GP CRI and CRII shown as black or stippled
boxes, respectively. Region III is boxed in the AGP and the transcription start site is represented by an arrow in the GP. Mutant 8 is the same as that shown
in Fig. 5. Mutant 11 contains the first 66 bases of the AGP shown in bold, which include the AGP CRI and Region III, linked to bases 67–90 of the GP.
Mutant 12 is the same as mutant 11 except that nonviral sequences (underlined) are substituted in place of bases 20–50. Mutants 13 and 14 are the same
as Mutant 12, except that nonviral sequences (underlined) are only found from bases 20–35 (Mutant 13) or 36–50 (Mutant 14). Replication levels are
expressed as percentages of the levels determined for the WT AGP minigenome (113-GL-AGP; average  SD). Representative Northern blots of replication
levels are shown in B.
354 M.A. Keller, G.D. Parks / Virology 306 (2003) 347–358
WT GP levels. This result is consistent with previous results
with SeV and RSV chimeric promoters, where it has been
shown that transfer of increasing amounts of AGP sequence
to the GP increased replication efficiency, but this increase
did not strictly correlate with a decrease in transcription
efficiency (Calain and Roux, 1995; Fearns et al., 2000).
Taken together, these results support the proposal that the
AGP Region III is not the sole determinant of differences in
AGP and GP replication efficiency, and that the GP cannot
be converted to a stronger promoter for replication by sim-
ply eliminating transcription.
The SV5 GP contains CRI and CRII elements that are
similar but not identical in sequence to those found in the
AGP (Fig. 1), suggesting that exchanges of CRI and CRII
between the promoters would not have a significant effect
on replication. CRII alone could be exchanged between
promoters without significantly altering the level of RNA
replication (Fig. 3). By contrast, exchanging CRI between
the two promoters led to reduction in replication levels from
any of the chimeric promoters (Fig. 3, Mutants 1, 3, 4 and
6). It was unexpected that replacing the GP CRI with the
AGP CRI resulted in decreases in RNA replication since we
hypothesized that any transferring AGP sequence would
result in increases in RNA replication from the chimeric
promoters. Taken together, this indicates that the ability of
CRI to effect RNA replication is not only dependent on the
primary sequence of CRI, but also the context in which the
CRI element is recognized. In other words, the AGP CRI
can function optimally with AGP sequence, whereas AGP
CRI with GP sequences decreases RNA replication (Figs. 3
and 4). Our results demonstrate that a chimeric promoter
containing CRI  Region III together showed a reproduc-
ible enhancement of RNA replication to approximately 40%
that seen with the AGP (Fig. 5, Mutant 8). Thus, the AGP
CRI, or CRICRII, decreases RNA replication when trans-
ferred to the GP alone, but CRI  Region III of the AGP
can function together to partially increase RNA replication
from the GP. Region III may act to enhance RNA replica-
tion from the AGP by interacting with the AGP CRI. Con-
versely, Region III could not exert this positive effect when
combined with the GP CRI (Fig. 3, Mutant 4; Fig. 4,
Mutants 7 and 9) Specifically, the three bases that differ
between CRI of the GP and AGP are important for RNA
replication from each promoter, possibly by interacting with
the intervening sequence of either promoter in the correct
context. This is consistent with results from extensive mu-
tagenesis of the RSV and HPIV3 promoters in which
changes in certain nucleotides within the 3 terminal GP
altered minigenome replication (Fearns et al., 2000; Hoff-
man and Bannerjee, 2000a). We propose that the SV5 GP
CRI sequences contain a negative-acting signal, since trans-
fer to the AGP significantly reduces RNA replication. For
reasons that are presently unclear, a minigenome containing
CRI, CRII, and Region III in the GP did not result in
increased RNA replication and resembled a WT GP. This
inclusion of CRII together with CRI and Region III from the
AGP reduced the enhancement seen when CRI Region III
was substituted into the GP (Fig. 5, Mutant 8). Because
exchanges of CRII between the AGP and GP had no effects
in any other context (Fig. 3, Mutants 2 and 5; Fig. 4, Mutant
9), we hypothesize that this chimera may be defective for an
unusual reason, such as producing a nascent RNA that is not
properly encapsideated because of incorrect folding (see
below).
We have found that the GP can direct RNA synthesis to
levels approaching that of the AGP when the 3 terminal 66
bases are derived from the AGP (Fig. 5). This transferred
region includes that AGP CRI, Region III, and the segment
between CRI and Region III from bases 20–50. Mutant 5 in
Fig. 3 shows that RNA replication is significantly decreased
when the AGP CRI is replaced with CRI from the GP and
essentially converts the AGP to a GP. This led us to believe
that a negative-acting signal for replication is present in the
GP that begins in CRI and extends into the intervening
region between CRI and CRII of the GP.
A key result from our study was the finding that high
replication can also be achieved by substituting bases 20–50
of the GP with nonviral sequences, but only in the context
of the AGP CRI and Region III. We have previously shown
that substitution of a similar nonviral sequence into the
corresponding segment of the AGP did not affect RNA
replication levels (Murphy et al., 1998). We conclude from
these results that the SV5 GP contains an element beginning
in the GP CRI and spans bases 20–50 that has a negative
effect on RNA replication, since replacement with nonviral
sequences, of bases 20–50 in the context of the AGP CRI
and Region III, enhances replication. Although we have not
carried out extensive mutational analysis of the negative-
acting sequence, RNA replication could not be enhanced by
substituting nonviral sequence into either the 3 or the 5
half of the 20–50 base segment. For SeV, it has previously
been shown that GP replication efficiency was increased by
substitutions in GP bases 24–55 (Calain and Roux, 1993),
and this corresponds well with bases 20–50 located between
the SV5 CRI and Region III. Thus, the presence of a
negative-acting element for RNA replication may be a com-
mon feature of the GP for other paramyxoviruses.
Our original hypothesis was that positive-acting signals
from the AGP could be transferred to the GP as discreet
elements to increase RNA replication from the GP. Our
results are inconsistent with this straightforward hypothesis
and instead suggest a more complicated model in which the
level of RNA replication from the SV5 promoters is defined
by a combination of negative- and positive-acting sequences
within the first 66 bases of the genome and antigenome.
This model is supported by two lines of evidence. First,
transfer of the AGP CRI and Region III element in combi-
nation confer a partial enhancement of replication to the GP.
We propose that these two AGP elements contain positive-
acting sequences that promote RNA replication, since our
previous work has shown that replacement of these regions
in the AGP with nonviral sequences decreases replication
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(Keller et al., 2001; Murphy et al., 1998). Second, we
propose that the GP contains a negative-acting sequence
that inhibits RNA replication that begins in CRI of the GP
and extends to the location of Region III in the chimeric
promoters (Figs. 4 and 5, Mutants 7–14). Together, it is only
the combination of positive-acting CRI and Region III cou-
pled with the removal of inhibitory sequences that can
account for the differences in RNA replication directed by
the GP and AGP.
Current models for paramyxovirus RNA replication in-
volve signals that are located on both the nucleocapsid
template and the nascent chain RNA that emerges from the
viral polymerase and must be encapsidated by NP (Gubbay
et al., 2001; Lamb and Kolakofsky, 2001). Based on the
structure of the SeV nucleocapsid derived from electron
micrographs (Egelman et al., 1989), we have previously
proposed a model for the structure of the SV5 AGP that
predicts that CRI and CRII are aligned on the same face of
the helical nucleocapsid (Murphy et al., 1998). We have
proposed that CRI and CRII are discontinuous elements
brought together through turns of the nucleocapsid helix to
serve as a binding site to position the viral polymerase at the
ultimate 3 end of the template (Murphy et al., 1998; Mur-
phy and Parks, 1999). Although recent imaging studies
suggest that SV5 differs from SeV in the number of NP
subunits per turn of the helical nucleocapsid (Bhella et al.,
2002), our proposed role for the SV5 CRI and CRII on the
template is consistent with our finding that RNA replication
from the AGP is very sensitive to small changes in the
spacing of CRI and CRII (Murphy et al., 1998). In our
model, Region III and the negative-acting segment con-
tained in bases 20–50 of the GP map to the opposite face of
the helix (Keller et al., 2001), suggesting that these seg-
ments function in RNA replication at a step other than on
the template.
Encapsidation of newly synthesized viral RNA by NP is
an essential step in paramyxovirus RNA replication (Lamb
and Kolokofsky, 2001) and may function to increase the
processivity of the viral polymerase (Gubbay et al., 2001;
Vidal and Kolokofsky, 1989). Thus, a promoter element
that enhances RNA replication could function as a signal on
the nascent RNA strand to promote encapsidation by the NP
protein as the RNA emerges from the viral polymerase.
Thus, the negative-acting GP signals in CRI and bases
20–50 could function to decrease encapsidation of the nas-
cent RNA strand by creating an RNA secondary structure
that is not well recognized by NP. This would result in low
levels of replication and predominantly transcription from
the GP, which we have observed in minigenome assays
(Fig. 2). In our model, CRII functions along with CRI on the
template to align the viral polymerase for initiation at the 3
end of the RNA, but the essential CRII element is not itself
a determinant of high-level RNA replication. By contrast,
our results support a model whereby the level of RNA
replication is determined by the first 66 bases of SV5 RNA.
Together, the AGP CRI and Region III, or the negative-
acting signal in the GP, function as part of a nascent RNA
chain to modulate replication at the level of encapsidation.
Sequences located at the ends of the paramyxovirus
RNA genome can play important roles in the viral life cycle
that extend beyond the control of RNA synthesis and pack-
aging of viral RNA into progeny virions. Striking examples
of a role for the viral promoters in pathogenesis have been
reported for recombinant SeV mutants containing ex-
changes of the GP with AGP sequences (Garcin et al., 1998)
or in naturally occurring field isolates with changes in GP
sequences (Fujii et al., 2002). Work is in progress to deter-
mine the effect of altering the ability of the GP or AGP to
direct replication on the noncytopathic nature of WT SV5
infections.
Materials and methods
Cells and viruses
Monolayer cultures of A549 human lung cells were
grown and infected with virus as previously described
(Murphy and Parks, 1997). Recombinant vaccinia virus
(vTF7.3) expressing the T7 RNA polymerase (Fuerst et al.,
1986) was grown and titered in CV1 cells.
Construction of plasmids containing SV5 genomic or
chimeric promoters
cDNAs encoding the minigenome analogs were flanked
on the 5 and 3 ends by the T7 polymerase promoter and
DNA encoding the hepatitis delta virus ribozyme, respec-
tively (Murphy and Parks, 1997; Pattnaik et al., 1992). All
minigenomes were constructed such that the product gen-
erated by the T7 polymerase would be genomic sense RNA
containing a 113-base 5 L-tr end and various 3 end pro-
moters derived from AGP, GP, or nonviral sequences. The
minigenome containing the wild-type SV5 AGP is desig-
nated 113-GL-AGP, which 113 SV5-specific 5-terminal
nucleotides linked to the Green Lantern (GL; Gibco BRL)
open reading frame followed by the terminal 90 bases of 3
antigenomic RNA (corresponding to the SV5 AGP). The
minigenome containing the wild-type GP of SV5 is desig-
nated 113-GL-90GP and is exactly the same as 113-GL-
AGP, except that it contains the first 90 bases of 3 genomic
RNA. To construct 113-GL-90GP, a plasmid encoding a
dicistronic internal deletion-type minigenome (pMF2;
Rassa and Parks, 1999) was digested with EcoRI and
Asp718 and used in a PCR along with SP6 primer and an
internal primer that introduced a StuI site adjacent to the
90-base leader-NP region. The resulting product was di-
gested with StuI and SphI and inserted into the correspond-
ing site in 113-GL-90B/Not-KO, a plasmid in which the
NotI site normally found in the GL sequence has been
deleted. Details of the mutagenesis procedures used to creat
individual minigenomes are available on request from the
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authors. Briefly, insertions, deletions, and chimeric promot-
ers were generated using the megaprimer method (Parks,
1994) with an internal primer to introduce the mutation and
SP6 primer. The resulting PCR products were digested with
StuI and SphI and inserted into the corresponding site of
113-GL-AGP/Not-KO. The nucleotide sequence of all
PCR-derived DNA segments was determined.
Analysis of in vivo RNA synthesis from cDNA-derived
components
Dishes (3.5 cm) of A549 human lung cells were infected
(multiplicity of infection 5) for 1 h with vTF7.3 (Fuerst et
al., 1986). These cells were subsequently cotransfected with
the plasmid containing the minigenome of choice (1 g)
and three support plasmids: pGem3-L (2 g), pGem3-P (0.2
g), and pUC19-NP (3 g), as described previously (Mur-
phy and Parks, 1997), using Lipofectin reagent for Fig. 2.
For Figs. 3–5, FuGene 6 reagent (Roche, Indianapolis, IN)
was used in place of Lipofectin for improved transfection
efficiency. Control plasmid (pGem3) was used to normalize
the amount of transfected DNA. RNA was harvested from
two 3.5-cm dishes using Trizol reagent at 40–48 h post-
transfection. To analyze RNA replication, cell lysates were
treated with micrococcal nuclease prior to Trizol extraction
as described (Peeples and Collins, 2000; Keller et al., 2001).
To analyze transcription products, purified RNA was se-
lected using oligo(dT) (Rassa and Parks, 1999). All RNAs
were analyzed by Northern blotting as described previously.
A 32P-labeled minus-sense GL-specific riboprobe (Mur-
phy et al., 1998) was generated from BamHI-linearized
pGem2-GL by SP6 RNA polymerase in the presence of
[32P]CTP. Membranes were hybridized with purified ribo-
probes for 1 h at 70°C in ExpressHyb (Clontech, Palo Alto,
CA). The membranes were then washed three times for 15
min with 2 SSC/0.1% SDS, 0.2 SSC/0.1% SDS, and
0.1 SSC/0.1% SDS, respectively. RNA levels were quan-
titated using PhosphorImager analysis and are expressed as
percentages of the 113-GL-AGP or 113-GL-GP wild-type
levels.
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